MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ejh.12073

Медицинская библиотека · European journal of haematology · 2013

Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.

Park Sophie, Labopin Myriam, Yakoub-Agha Ibrahim, Delaunay Jacques, Dhedin Nathalie, Deconinck Eric, Michallet Mauricette, Robin Marie, De Revel Thierry, Bernard Marc, Vey Norbert, Lioure Bruno, Lapusan Simona, Tabrizi Reza, Bourhis Jean-Henri, Huynh Anne, Beguin Yves, Socié Gérard, Dreyfus François, Fenaux Pierre, Mohty Mohamad

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVES AND

METHODS

Chronic myelomonocytic leukemia (CMML) is a severe disease for which allogeneic stem cell transplantation (allo-SCT) remains the only potentially curative treatment. We describe a retrospective study determining prognostic factors for outcome after allo-SCT in consecutive 73 patients with CMML reported to the SFGM-TC registry between 1992 and 2009.

RESULTS

At diagnosis, median age was 53 yrs, and 36% patients had palpable splenomegaly (SPM). 48, 13, and 9 patients had good, intermediate, and poor risk karyotype, respectively, according to IPSS, 61% patients had CMML-1, and 39% had CMML-2. 41/31/1 cases had an HLA-identical sibling, an unrelated and haploidentical donor, respectively. 43 patients received reduced-intensity conditioning. With a median follow-up of 23 month, acute grade 2-4 and chronic GVHD developed in 21 and 25 patients, respectively. The 3-year OS, NRM (non-relapse mortality),EFS, and CIR (cumulative incidence of relapse) were 32%, 36%, 29% and 35%, respectively. OS was not influenced by the CR status, marrow blasts% at allo-SCT, prior treatments, and cGVHD. Using multivariate analysis, year of transplant < 2004 (YOT) (P = 0.005) was associated with higher NRM, YOT <2004 (P = 0.04) and SPM at allo-SCT (P = 0.02) with lower EFS, and YOT < 2004 (P = 0.03) and SPM at allo-SCT (P = 0.04) with poorer OS.

CONCLUSIONS

Allogeneic stem cell transplantation is a valid treatment option for patients with CMML, and its outcome has improved with YOT > 2004. Splenomegaly seems to be a negative factor of OS and EFS in this series.

Для цитирования: Park Sophie, Labopin Myriam, Yakoub-Agha Ibrahim, Delaunay Jacques, Dhedin Nathalie, Deconinck Eric, Michallet Mauricette, Robin Marie, De Revel Thierry, Bernard Marc, Vey Norbert, Lioure Bruno, Lapusan Simona, Tabrizi Reza, Bourhis Jean-Henri, Huynh Anne, Beguin Yves, Socié Gérard, Dreyfus François, Fenaux Pierre, Mohty Mohamad. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.. European journal of haematology. 2013. DOI: 10.1111/ejh.12073.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.